Rockville-based Emergent BioSolutions, whose anthrax vaccine BioThrax is driving revenue growth, will move toward final clinical trials for its next generation anthrax vaccine with a $31 million BARDA contract.
Gaithersburg-based Emergent BioSolutions Inc. is adding a $31 million contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority to its ongoing work developing a next-generation anthrax vaccine.
21:52 Netflix nears 94 million subscribers 10 years after streaming launch10
22:33 Allergan to pay $15 million over failing to disclose merger talks18
21:40 HP Enterprise to buy cloud software company SimpliVity19
23:29 Fear Spurs Support for Health Law as Republicans Work to Repeal It17